{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-079822","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2023-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.033340+00:00","generated_at":"2026-06-13T10:24:24.958209+00:00","sec_items":["1.01","2.03","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Armata Pharma secures $25M loan from Innoviva, appoints Dr. Deborah Birx as CEO","bullets":["Enters $25M secured term loan with Innoviva Strategic Opportunities LLC at 14% interest, matures Jan 2025.","Extends existing convertible credit agreement maturity to Jan 2025 via amendment.","Terminates CEO Brian Varnum; appoints Dr. Deborah Birx, former White House Coronavirus Task Force coordinator, as CEO and director.","Proceeds to advance phage candidates AP-PA02 (Pseudomonas) and AP-SA02 (Staph) and build out cGMP manufacturing facility.","Resets 2023 annual meeting date from Aug 29 to Sep 14, 2023; record date unchanged at July 10, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-079822","json":"https://secwatch.observer/filing/0001104659-23-079822.json","markdown":"https://secwatch.observer/filing/0001104659-23-079822.md","text":"https://secwatch.observer/filing/0001104659-23-079822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/tm2321012d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:24:24.958209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a66781fbe7b08772457ab09a3eff60f984f30a34","claim":"Armata Pharmaceuticals, Inc. incurred term loan of $25 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 10, 2025.","evidence_excerpt":"The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 10, 2025.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$25 million"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC"},{"label":"Rate","value":"14.0% per annum"},{"label":"Maturity","value":"January 10, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ca479e05f9facfa72636142090255929f384b712","claim":"Armata Pharmaceuticals, Inc. amended convertible notes with Innoviva maturing January 10, 2025.","evidence_excerpt":"the parties agreed to, among other things, extend the maturity date from January 10, 2024, to January 10, 2025.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Counterparty","value":"Innoviva"},{"label":"Maturity","value":"January 10, 2025"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"07abea9170","claim":"Deborah Birx was appointed as Chief Executive Officer at Armata Pharmaceuticals, Inc..","evidence_excerpt":"On July 11, 2023, the Company announced that the Board of Directors (the “Board”) had appointed Dr. Deborah Birx, 67, to the position of Chief Executive Officer and as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f93e17f6d0","claim":"Brian Varnum was terminated as Chief Executive Officer at Armata Pharmaceuticals, Inc..","evidence_excerpt":"On July 10, 2023, the Company terminated Dr. Brian Varnum as its Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"565dade0374a05e3b029394251df8f05b01f54fd","claim":"Armata Pharmaceuticals, Inc. entered into Credit Agreement with Innoviva Strategic Opportunities LLC valued at $25 million (effective 2023-07-11).","evidence_excerpt":"On July 11, 2023, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that it had entered into, as borrower, a credit and security agreement (the “Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc. (the “Parent”), a principal shareholder of the Company on July 10, 2023. The Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 10, 2025.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC"},{"label":"Value","value":"$25 million"},{"label":"Effective","value":"2023-07-11"}],"fact_type":"material_agreement"},{"claim_id":"a10f627b57b510c833220a2ddc8a03d6d7515757","claim":"Armata Pharmaceuticals, Inc. amended First Amendment to Convertible Credit Agreement with Innoviva (effective 2023-07-11).","evidence_excerpt":"Concurrently with the execution of the Credit Agreement, the Company entered into an amendment to that certain secured convertible credit and security agreement (the “First Amendment to Convertible Credit Agreement”), dated January 10, 2023, by and among the Company, as borrower, Innoviva, as lender, and certain domestic subsidiaries and foreign material subsidiaries of the Company, as guarantors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Innoviva"},{"label":"Effective","value":"2023-07-11"}],"fact_type":"material_agreement"},{"claim_id":"e246387c66e9e61608e5af5642c8ae188362e7c8","claim":"Armata Pharmaceuticals, Inc. amended First Amendment to Second A&R Voting Agreement with Innoviva and Innoviva, Inc. (effective 2023-07-11).","evidence_excerpt":"In addition, the Company concurrently entered into an amendment (the “First Amendment to Second A&R Voting Agreement”) to its Second Amended and Restated Voting Agreement, dated as of February 9, 2022, by and among the Company, Innoviva and the Parent to extend the expiration date to the earlier of the fifth anniversary of the effective date, or February 9, 2027, and the date of receipt of approval by the U.S. Food and Drug Administration of any of the product candidates of the Company for marketing and commercial distribution.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923079822/0001104659-23-079822-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Innoviva and Innoviva, Inc."},{"label":"Effective","value":"2023-07-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}